Reply to Office Action of July 17, 2009

## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Docket No.: 2002.750US

## **Listing of Claims:**

1. (Previously Presented) A tetrahydroquinoline derivative according to Formula 1,

Formula I

or a pharmaceutically acceptable salt thereof, wherein

R<sup>1</sup> and R<sup>2</sup> are H or Me

R<sup>3</sup> is H, hydroxy, (1-4C)alkoxy,

R<sup>4</sup> is H, OH, or (1-4C)alkoxy,

 $R^5$  is OH, (1-4C)alkoxy or  $R^7$ ,

with the proviso that if R<sup>4</sup> is H, R<sup>5</sup> is not OH or (1-4C)alkoxy

R<sup>6</sup> is (2-5C)heteroaryl, (6C)aryl, (3-8C)cycloalkyl, or (1-6C)alkyl,

wherein the (2-5C)heteroaryl and the (6C)aryl are optionally substituted with one or more substituents selected from hydroxyl, amino, halogen, phenyl, (1-4C)alkyl, (1-4C)alkoxy, or (1-4C)(di)alkylamino,

R<sup>7</sup> is amino, (di)(1-4C)alkylamino, (2-5C)heteroarylcarbonylamino, (2-

5C)heteroarylcarbonyloxy, R<sup>8</sup>-(2-4C)alkoxy, R<sup>9</sup>-methylamino or R<sup>9</sup>-methoxy

R<sup>8</sup> is amino, (di)(1-4C)alkylamino, (2-6C)heterocycloalkyl, (2-

6C)heterocycloalkylcarbonylamino, or (1-4C)alkoxycarbonylamino and

Application No. 10/540,336 Amendment dated January 19, 2010 Reply to Office Action of July 17, 2009

R<sup>9</sup> is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (2-5C)heteroaryl, optionally substituted with one or more (1-4C)alkyl substituents, or (6C)aryl.

Docket No.: 2002.750US

- 2. (Cancelled).
- 3. (Cancelled).
- 4. (Previously Presented) The tetrahydroquinoline derivative of claim 1 wherein R<sup>8</sup> is amino, (di)(1-4C)alkylamino, (2-6C)heterocycloalkyl or (2-6C)heterocycloalkylcarbonylamino.
- 5. (Previously Presented) The tetrahydroquinoline derivative of claim 1 wherein R<sup>7</sup> is (di)(1-4C)alkylamino, R<sup>8</sup>-(2-4C)alkoxy, R<sup>9</sup>-methylamino or R<sup>9</sup>-methoxy.
- 6. (Previously presented) The tetrahydroquinoline derivative of claim 5 wherein R<sup>8</sup> is amino, (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.
- 7. (Previously presented) The tetrahydroquinoline derivative of claim 6 wherein R<sup>8</sup> is (di)(1-4C)alkylamino or (2-6C)heterocycloalkyl.
  - 8. (Cancelled).
- 9. (Previously Presented) The tetrahydroquinoline derivative of claim 5 wherein R<sup>6</sup> is (2-5C)heteroaryl or (6C)aryl.
- 10. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R<sup>6</sup> is (4-5C)heteroaryl or (6C)aryl and R9 is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.
- 11. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R<sup>7</sup> is (di)(1-4C)alkylamino, R<sup>8</sup>-ethoxy, R<sup>9</sup>-methylamino or R<sup>9</sup>-methoxy and R<sup>9</sup> is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.

Application No. 10/540,336 Docket No.: 2002,750US Amendment dated January 19, 2010

Reply to Office Action of July 17, 2009

12. (Previously presented) The tetrahydroquinoline derivative of claim 1 wherein R<sup>8</sup> is (di)(1-4C)alkylamino or (4-5C)heterocycloalkyl and R<sup>9</sup> is aminocarbonyl, (di)(1-4C)alkylaminocarbonyl, (3-5C)heteroaryl or (6C)aryl.

- 13. (Previously presented) A pharmaceutical composition comprising the tetrahydroquinoline derivative of claim 1 and at least one pharmaceutically suitable auxiliary.
  - 14. (Cancelled)
  - 15. (Cancelled)
  - 16. (Cancelled)